It’s only fair to share… Lomonitinib CAS 2923221-56-9 MF C27H24N4O2 MW436.5 g/mol 3-(3,4-dimethoxyphenyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrazolo[4,5-c]quinoline 3-(3,4-dimethoxyphenyl)-1-(1,2,3,4-tetrahydroisoquinolin-7-yl)-1H-pyrazolo[4,3-c]quinolinetyrosine kinase inhibitor, antineoplastic, ZE46-0134, Eilean Therapeutics, U4DPU7W7QU Lomonitinib (also known as ZE46-0134) is a highly potent, selective, orally bioavailable pan-FLT3 and IRAK4 small molecule inhibitor being developed for the treatment of Acute Myeloid Leukemia (AML). Developed by Eilean Therapeutics in collaboration with …
Tag «anax labs»
Lixosicone
It’s only fair to share… Lixosicone CAS 1610878-71-1 MF C29H40O3 MW 436.6 g/mol 1-[(3S,8S,9S,10R,13S,14S,17S)-3-[(4-methoxyphenyl)methoxy]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone 3β-[(4-methoxyphenyl)methoxy]pregn-5-en-20-onecannabinoid CB1 receptor signalling inhibitor, AEF0117, AEF 0117, 9LG9CT78SV AEF0117 is a small molecule drug. AEF0117 is under investigation in clinical trial NCT05554926 (Study of [4-14C] AEF0117 Following a Single Oral Dose in Healthy Male Subjects). Lixosicone (AEF0117, 3β-(4-methoxybenzyloxy)pregn-5-en-20-one) is a compound derived from pregnenolone by …
Lirucitinib
It’s only fair to share… Lirucitinib CAS 2458115-78-9 MF C16H25N5OS MW335.5 g/mol N-[4-[(ethylsulfonimidoyl)methyl]cyclohexyl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine (R)-ethyl(imino)({trans-4-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclohexyl}methyl)-λ6-sulfanoneJanus tyrosine kinase inhibitor, anti-inflammatory, GGW101, GGW 101 Lirucitinib is a Janus kinase (JAK) inhibitor primarily known as a novel, Class I veterinary drug. It specifically targets the JAK1 enzyme to block itch-inducing (pruritic) and inflammation-causing cytokines in the body. Core Information SYN …
Linvemastat
It’s only fair to share… Linvemastat CAS 2389060-50-6 MF C20H17N3O4S MW395.43 5-[3-[4-[(2-methyl-4-pyridinyl)methoxy]phenyl]sulfanylfuran-2-yl]imidazolidine-2,4-dione matrix metalloproteinase-12 inhibitor, lung diseases, FP 020, FP2AMM4SVF Linvemastat (also known by its developmental code FP-020) is an investigational, orally active small-molecule drug designed to selectively inhibit matrix metalloproteinase-12 (MMP-12). It is being developed as a potential disease-modifying therapy for chronic inflammatory and …
Gadoquatrane
It’s only fair to share… Gadoquatrane CAS2048221-65-2MW2579.0 g/mol FDA 2026, APPROVALS 2026, Ambelvist, OZG7J613HK, BAY-1747846, BAY 1747846 2-[4,10-bis(carboxylatomethyl)-7-[1-oxo-1-[[2-oxo-2-[[3-[[2-[2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetyl]amino]-2,2-bis[[[2-[2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetrazacyclododec-1-yl]propanoylamino]acetyl]amino]methyl]propyl]amino]ethyl]amino]propan-2-yl]-1,4,7,10-tetrazacyclododec-1-yl]acetate;tetrakis(gadolinium(3+)) TETRAGADOLINIUM (4,10-BIS(CARBOXYLATOMETHYL)-7-(3,6,12,15-TETRAOXO-16-(4,7,10-TRIS-(CARBOXYLATOMETHYL)-1,4,7,10-TETRAAZACYCLODODECAN-1-YL)-9,9-BIS(((((2-(4,7,10-TRIS-(CARBOXYLATOMETHYL)-1,4,7,10-TETRAAZACYCLODODECAN-1-YL)PROPANOYL)AMINO)ACETYL)-AMINO)METHYL)-4,7,11,14-TETRAAZAHEPTADECAN-2-YL)-1,4,7,10-TETRAAZACYCLODODECAN-1-YL)ACETATE To detect and visualize lesions with abnormal vascularity, in conjunction with MRI Gadoquatrane (marketed as AMBELVIST®) is a low-dose, macrocyclic gadolinium-based contrast agent (GBCA) developed by Bayer for use in magnetic resonance imaging (MRI). It is …
Lasmotinib
It’s only fair to share… Lasmotinib CAS 2127107-15-5 MF C19H19FN4O2S MW386.4 g/mol 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide 3-(carbamoylamino)-5-[(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamidetyrosine kinase inhibitor, antineoplastic, PHI-101, PHI 101, U2UY9TBQ8Z Lasmotinib (also known by its research code PHI-101) is a next-generation, orally bioavailable targeted cancer therapy. It functions as a dual FLT3 and CHK2 inhibitor. It is primarily being investigated to treat Acute Myeloid Leukemia …
Larubrilstat
It’s only fair to share… Larubrilstat CAS 2765226-31-9 MF C21H25N5O2 MW379.5 g/mol [2-[[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino]pyrimidin-5-yl]-(8-oxa-2-azaspiro[4.5]decan-2-yl)methanone (2-{[(5R)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl]amino}pyrimidin-5-yl)(8-oxa-2-azaspiro[4.5]decan-2-yl)methanonevascular non-inflammatory molecule-1 (VNN1) inhibitor, AG6K4Y29B4 Larubrilstat is the International Nonproprietary Name (INN) for an experimental, small-molecule vascular non-inflammatory molecule-1 (VNN1) inhibitor. VNN1, also commonly known as Vanin-1 or pantetheinase, is an enzyme involved in tissue response to oxidative stress and inflammation. Current …
Lanoracopan
It’s only fair to share… Lanoracopan CAS 2797066-85-2 MFC27H32N2O4 MW448.6 g/mol 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid Benzoic acid, 4-[(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]-2-piperidinyl]- 4-{(2S,4S)-4-(cyclopropylmethoxy)-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl}benzoic acidcomplement factor B inhibitor, MY 008211A, Factor B-IN-5, Y5UN7AE8SF Lanoracopan (also known by its developmental code MY008211A or Factor B-IN-5) is an investigational small-molecule drug that acts as a potent complement factor B (CFB) inhibitor. It is designed to …
Lanisidenib
It’s only fair to share… lanisidenib, anax labs, isocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J Cas 2135537-20-9 MF C28H23ClF3N5O4S MW618.03 g/mol (3S)-N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-1,1-dioxo-1,2-thiazolidine-3-carboxamide IUPAC Name: (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3, 3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo-1λ⁶,2-thiazolidine-3-carboxamide 3-Isothiazolidinecarboxamide, N-[(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-2-(4-cyano-2-pyridinyl)-N-(3-fluorophenyl)-, 1,1-dioxide, (3S)- (3S)-N-{(1S)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl}-2-(4-cyanopyridin-2-yl)-N-(3-fluorophenyl)-1,1-dioxo1λ6,2-thiazolidine-3-carboxamideisocitrate dehydrogenase inhibitor, antineoplastic, G5J396CG5J Lanisidenib is a potent, selective isocitrate dehydrogenase (IDH) inhibitor that exhibits antineoplastic (anti-cancer) activity. It works by targeting abnormal IDH enzymes, which …
Itareparib
It’s only fair to share… Itareparib CAS 1606995-47-4 MF C20H26FN3O2 MW359.4 g/mol 2-(1-Cyclohexyl-4-piperidinyl)-6-fluoro-2,3-dihydro-3-oxo-1H-isoindole-4-carboxamide 1H-ISOINDOLE-4-CARBOXAMIDE, 2-(1-CYCLOHEXYL-4-PIPERIDINYL)-6-FLUORO-2,3-DIHYDRO-3-OXO- 2-(1-cyclohexylpiperidin-4-yl)-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole4-carboxamidepoly (ADP-ribose) polymerase (PARP) inhibitor, antineoplastic, NMS-03305293, NMS-293, NMS 03305293, NMS 293, KFI1190L8L, NV 578, Itareparib is the inhibitor for PARP and exhibits antineoplastic activity. Itareparib (development code NMS-03305293 or NMS-293) is an experimental, next-generation PARP1-selective oral inhibitor being developed by the biopharmaceutical …